On January 17th, 2026, the Biodiversity Beyond National Jurisdiction (“BBNJ”) Agreement, also known as the “High Seas Treaty”, entered into force. For the first time, companies that use marine genetic resources (“MGRs”) and digital sequence information (“DSI”) originating from areas beyond national jurisdiction may be required to share monetary and non-monetary benefits at a global level.
This marks a significant expansion of access and benefit-sharing (“ABS”) obligations for companies. Until now, under the Convention on Biological Diversity (“CBD”) and its Nagoya Protocol, ABS obligations applied only to genetic resources originating within national jurisdictions. The BBNJ Agreement fundamentally changes this landscape: companies in pharmaceuticals, biotechnology, cosmetics, food and feed that rely on marine-derived compounds, microorganisms or genetic data may now face new reporting and annual payment obligations.
Companies should not assume a long transition period. Implementation is already advancing. The European Commission has published a draft Directive (“draft EU Directive”), and the United Kingdom adopted the Biodiversity Beyond National Jurisdiction Act 2026 (“UK Act”) on February 12th, 2026. Companies should therefore assess now whether their R&D pipelines, data use practices, or product portfolios fall within scope.
In this blog, we examine how the BBNJ Agreement and its EU and UK implementation could affect companies using MGRs and DSI, and identify the key compliance risks and strategic questions for in-house counsel and senior management.Continue Reading Navigating the new UN High Seas Treaty: Key Compliance Risks for Life Sciences Companies